The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksUpdated•Originally published 13 April 2026•Updated 14 April 2026•

1 min read

Theralase Technologies Achieves 100% Response in Bladder Cancer Preclinical Study

Key Facts

1Theralase Technologies closed a total financing of $CAN 2.66 million through a private placement and a line of credit.

2The company issued 6,404,700 units at a price of $CAN 0.26 per unit in the private placement.

about 2 months ago

Version History

Version 1about 2 months ago

What changed: Updated the story from a pure funding update to a clinical milestone reporting 100% success in preclinical trials for bladder cancer.

Theralase Technologies Inc. (TSXV: TLT) has announced a significant clinical milestone, achieving a 100% complete response in a preclinical study for Muscle Invasive Bladder Cancer (MIBC). The study utilized the company's X-Ray-activated Rutherrin technology, proving that treated subjects remained entirely cancer-free. These results showed a stark contrast to control groups that were either untreated or received radiation therapy alone. This breakthrough follows the company's recent successful financing round of 2.66 million Canadian dollars intended for R&D. Management intends to leverage these findings to further develop energy-activated small molecules designed to target and destroy malignant cells. This successful preclinical outcome provides a strong foundation for the firm's advancing clinical pipeline.